LAPTM5 and graft versus host disease: LAPTM5, Laptm5, a lysosomal transmembrane protein enhancing the degradation of several targets involved in immune signaling (such as ubiquitin-editing enzyme A20), has been validated to be participate in the modulation of the lethal T cell alloreactivity mediated by dendritic cells and immunoreactions in multiple inflammatory disease, such as host versus graft disease (GVHD) (Glowacka et al., 2012; Hubbard-Lucey et al., 2014).